Literature DB >> 25788713

Availability of N-Methyl-d-Aspartate Receptor Coagonists Affects Cocaine-Induced Conditioned Place Preference and Locomotor Sensitization: Implications for Comorbid Schizophrenia and Substance Abuse.

Matthew D Puhl1, Alexandra R Berg1, Anita J Bechtholt1, Joseph T Coyle2.   

Abstract

Schizophrenia is associated with high prevalence of substance abuse. Recent research suggests that dysregulation of N-methyl-d-aspartate receptor (NMDAR) function may play a role in the pathophysiology of both schizophrenia and drug addiction, and thus, may account for this high comorbidity. Our laboratory has developed two transgenic mouse lines that exhibit contrasting NMDAR activity based on the availability of the glycine modulatory site (GMS) agonists d-serine and glycine. Glycine transporter 1 knockdowns (GlyT1(+/-)) exhibit NMDAR hyperfunction, whereas serine racemase knockouts (SR(-/-)) exhibit NMDAR hypofunction. We characterized the behavior of these lines in a cocaine-induced (20 mg/kg) conditioned place preference (CPP) and locomotor sensitization paradigm. Compared with wild-type mice, GlyT1(+/-) mice displayed hastened extinction of CPP and robust cocaine-induced reinstatement. SR(-/-) mice appeared to immediately "forget" the learned preference, because they did not exhibit cocaine-induced reinstatement and also displayed attenuated locomotor sensitization. Treatment of GlyT1(+/-) mice with gavestinel (10 mg/kg on day 1; 5 mg/kg on days 2-17), a GMS antagonist, attenuated cocaine-induced CPP and caused them to immediately "forget" the learned preference. Treatment of SR(-/-) mice with d-serine (300 mg/kg on day 1; 150 mg/kg on days 2-17) to normalize brain levels caused them to avoid the cocaine-paired side of the chamber during extinction. These results highlight NMDAR dysfunction as a possible neural mechanism underlying comorbid schizophrenia and substance abuse. Also, these findings suggest drugs that directly or indirectly activate the NMDAR GMS could be an effective treatment of cocaine abuse.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25788713      PMCID: PMC4429674          DOI: 10.1124/jpet.115.223099

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  46 in total

1.  Lifetime prevalence of psychotic and bipolar I disorders in a general population.

Authors:  Jonna Perälä; Jaana Suvisaari; Samuli I Saarni; Kimmo Kuoppasalmi; Erkki Isometsä; Sami Pirkola; Timo Partonen; Annamari Tuulio-Henriksson; Jukka Hintikka; Tuula Kieseppä; Tommi Härkänen; Seppo Koskinen; Jouko Lönnqvist
Journal:  Arch Gen Psychiatry       Date:  2007-01

Review 2.  Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms.

Authors:  Joseph T Coyle
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

3.  Reduced glycine transporter type 1 expression leads to major changes in glutamatergic neurotransmission of CA1 hippocampal neurones in mice.

Authors:  Marzia Martina; Marie-Eve B-Turcotte; Samantha Halman; Guochuan Tsai; Mario Tiberi; Joseph T Coyle; Richard Bergeron
Journal:  J Physiol       Date:  2005-01-20       Impact factor: 5.182

4.  Discordant behavioral effects of psychotomimetic drugs in mice with altered NMDA receptor function.

Authors:  Michael A Benneyworth; Alo C Basu; Joseph T Coyle
Journal:  Psychopharmacology (Berl)       Date:  2010-09-24       Impact factor: 4.530

5.  Substance abuse amplifies the risk for violence in schizophrenia spectrum disorder.

Authors:  Murat Erkiran; Havva Ozünalan; Cüneyt Evren; Sema Aytaçlar; Levent Kirisci; Ralph Tarter
Journal:  Addict Behav       Date:  2006-02-02       Impact factor: 3.913

6.  Changes in the magnitude of drug-unconditioned stimulus during conditioning modulate cocaine-induced place preference in mice.

Authors:  Yossef Itzhak; Karen L Anderson
Journal:  Addict Biol       Date:  2011-04-20       Impact factor: 4.280

Review 7.  Mechanisms of fear extinction.

Authors:  K M Myers; M Davis
Journal:  Mol Psychiatry       Date:  2006-12-12       Impact factor: 15.992

Review 8.  Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.

Authors:  Daniel C Javitt
Journal:  Int Rev Neurobiol       Date:  2007       Impact factor: 3.230

9.  Identification of brain nuclei implicated in cocaine-primed reinstatement of conditioned place preference: a behaviour dissociable from sensitization.

Authors:  Robyn Mary Brown; Jennifer Lynn Short; Andrew John Lawrence
Journal:  PLoS One       Date:  2010-12-29       Impact factor: 3.240

10.  Role of serine racemase in behavioral sensitization in mice after repeated administration of methamphetamine.

Authors:  Mao Horio; Mami Kohno; Yuko Fujita; Tamaki Ishima; Ran Inoue; Hisashi Mori; Kenji Hashimoto
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

View more
  6 in total

Review 1.  Fifty Years of Research on Schizophrenia: The Ascendance of the Glutamatergic Synapse.

Authors:  Joseph T Coyle; W Brad Ruzicka; Darrick T Balu
Journal:  Am J Psychiatry       Date:  2020-12-01       Impact factor: 18.112

2.  N-Methyl-d-aspartate receptor co-agonist availability affects behavioral and neurochemical responses to cocaine: insights into comorbid schizophrenia and substance abuse.

Authors:  Matthew D Puhl; Rajeev I Desai; Shunsuke Takagi; Kendall T Presti; Michelle R Doyle; Rachel J Donahue; Samantha M Landino; Jack Bergman; William A Carlezon; Joseph T Coyle
Journal:  Addict Biol       Date:  2017-11-23       Impact factor: 4.280

Review 3.  Do specific NMDA receptor subunits act as gateways for addictive behaviors?

Authors:  F W Hopf
Journal:  Genes Brain Behav       Date:  2016-11-18       Impact factor: 3.449

4.  Addiction: A preclinical and clinical analysis.

Authors:  Patricia Sue Grigson
Journal:  Brain Res Bull       Date:  2016-03-19       Impact factor: 4.077

5.  Serine Racemase Expression by Striatal Neurons.

Authors:  Shunsuke Takagi; Matthew D Puhl; Thea Anderson; Darrick T Balu; Joseph T Coyle
Journal:  Cell Mol Neurobiol       Date:  2020-05-22       Impact factor: 5.046

Review 6.  Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.

Authors:  James Maksymetz; Sean P Moran; P Jeffrey Conn
Journal:  Mol Brain       Date:  2017-04-26       Impact factor: 4.041

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.